8-K: TerrAscend Reports Q1 2025 Financial Results: Revenue $71 Million, Gross Profit Margin Up

TerrAscend announces its Q1 2025 financial results, highlighting a net revenue of $71 million and an improved gross profit margin of 51.8%.

Summary

• TerrAscend reported a net revenue of $71.0 million for Q1 2025, a 4.5% decrease compared to Q4 2024 due to seasonality.
• The gross profit margin increased to 51.8%, up 160 basis points from 50.2% in the previous quarter.
• GAAP Net Loss was $12.3 million, a significant improvement from the $30.2 million net loss in Q4 2024.
• EBITDA was $12.4 million, compared to an EBITDA loss of $30.6 million in Q4 2024.
• Adjusted EBITDA was $15.3 million, compared to $15.1 million in Q4 2024, with an Adjusted EBITDA Margin of 21.6%.
• Net cash provided by operating activities was $8.0 million, and free cash flow was $5.5 million.
• The company completed the acquisition of a dispensary in Ohio and signed a definitive agreement to acquire a dispensary in New Jersey after the quarter ended.
• TerrAscend repurchased 637,000 shares as part of its $10 million share repurchase program.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to improved profitability metrics (gross margin, EBITDA) and strategic acquisitions, despite a slight revenue decline. The company's focus on cost reduction and positive cash flow contribute to the positive outlook.

Positives

• Gross profit margin increased to 51.8%, up from 50.2% in Q4 2024.
• GAAP Net Loss decreased significantly to $12.3 million from $30.2 million in the previous quarter.
• Adjusted EBITDA increased to $15.3 million, with an Adjusted EBITDA Margin of 21.6%.
• The company achieved its 11th consecutive quarter of positive operating cash flow and 7th consecutive quarter of positive free cash flow.
• TerrAscend completed the acquisition of Ratio Cannabis in Ohio and signed an agreement to acquire a dispensary in New Jersey.
• General & Administrative expenses declined by $1.6 million in Q1, following a $3.6 million reduction in Q4 2024.
• The company repurchased 637,000 shares as part of the $10 million share repurchase program.

Negatives

• Net revenue decreased by 4.5% sequentially, from $74.4 million in Q4 2024 to $71.0 million in Q1 2025, due to seasonality.
• Net cash provided by operating activities decreased from $9.7 million in Q4 2024 to $8.0 million in Q1 2025.

Risks

• The cannabis industry faces significant legal restrictions and regulations in the United States.
• Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law.
• Enforcement of federal laws in the United States is a significant risk to TerrAscend's business.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

TerrAscend is well-positioned to drive further operational efficiencies, grow its core business, and strategically pursue additional acquisitions at increasingly attractive valuations, supported by a robust balance sheet and minimal debt maturities until late 2028.

Management Comments

• Jason Wild, Executive Chairman of TerrAscend, stated that despite a challenging industry environment, revenue performed in line with guidance, while gross margin and EBITDA margin outperformed expectations.
• Jason Wild noted that General & Administrative expenses declined by an additional $1.6 million in Q1, following a $3.6 million reduction in Q4 2024, as part of the ongoing G&A reduction program aimed at achieving $10 million in year-over-year savings for 2025.

Industry Context

TerrAscend's focus on margin expansion and cost reduction aligns with the broader cannabis industry's need to improve profitability amidst regulatory challenges and market competition. The company's strategic acquisitions and expansion in key states like Ohio and New Jersey reflect a trend of consolidation and geographic diversification among cannabis operators.

Comparison to Industry Standards

• While specific competitor data isn't provided, TerrAscend's gross margin of 51.8% is competitive within the cannabis industry, where margins can vary widely based on operational efficiency and market dynamics.
• Companies like Curaleaf and Green Thumb Industries, which are also multi-state operators, often report similar metrics, and comparing TerrAscend's performance against these peers would provide a more detailed benchmark.
• The achievement of positive free cash flow for seven consecutive quarters is a positive indicator, as many cannabis companies struggle with cash flow due to high capital expenditures and regulatory burdens.

Stakeholder Impact

• Shareholders may view the improved profitability and strategic acquisitions positively.
• Employees may benefit from the company's growth and expansion.
• Customers can expect continued access to high-quality cannabis products.
• Suppliers and creditors can be reassured by the company's positive cash flow and financial stability.

Next Steps

• Complete the acquisition of the dispensary in New Jersey, pending regulatory approval.
• Realize the benefits of the expanded cultivation capacity in Maryland, with the first harvest expected in late June.
• Continue the G&A reduction program to achieve $10 million in year-over-year savings for 2025.
• Monitor and prepare for potential adult-use implementation in Pennsylvania.

Key Dates

Keywords

TerrAscend, cannabis, financial results, Q1 2025, revenue, EBITDA, gross profit, dispensary, acquisition, OTCQX, TSNDF